What Palatin Technologies Inc does.

Palatin™ is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (“MCR”) system. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize product commercial potential.

The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. We believe that our MC1R agonist peptides have broad anti-inflammatory effects and utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. We are also developing peptides that are active at more than one melanocortin receptor and small molecule MCR agonists.

Revenue and profit, by fiscal year.

More on PTN.

• Palatin Technologies Inc summary
• Palatin Technologies Inc financial statements
• Palatin Technologies Inc key metrics
• Palatin Technologies Inc health scores and style box
• Palatin Technologies Inc earnings
• Palatin Technologies Inc dividends
• Palatin Technologies Inc valuation
• Palatin Technologies Inc ownership and insiders
• Palatin Technologies Inc peers

Figures from Palatin Technologies Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.